Lyme Disease Prevalence Formula (US-CCUC™ Aligned)
- Apr 12
- 9 min read
The True U.S. Lyme Disease Burden: Why Millions of Cases Are Missing from Official Counts
This paper is part of the CYNAERA Lyme Library, a growing resource, impacting how chronic Lyme is researched, treated and counted.
By Cynthia Adinig
Key Findings and Summary
CYNAERA’s US-CCUC™ prevalence model estimates that the true U.S. burden of Lyme disease is approximately 5 to 7 million American adults, far above the roughly 400,000 to 500,000 diagnoses captured annually in U.S. systems (CDC, 2024; Kugeler et al., 2021). Although Lyme disease is often presented as a regional infection with predictable recovery after early treatment, the real burden is much larger and more complex. Many cases are never recognized in the acute phase, while others progress into persistent, relapsing, multisystem illness that is inconsistently tracked, misclassified, or excluded from standard surveillance frameworks (Rebman and Aucott, 2020; Aucott et al., 2013).
The result is a structural mismatch between visible burden and total burden. CYNAERA’s US-CCUC™ framework corrects for that mismatch by accounting for underdiagnosis, diagnostic fragmentation, and chronic disease trajectories. Under this model, Lyme disease is reframed not as a narrowly counted regional infection, but as a major chronic illness burden that aligns with broader CYNAERA modeling across infection-associated chronic conditions, including the Corrected National Prevalence Estimates for Infection Associated Chronic Conditions paper. These estimates should also be interpreted within a broader IACC landscape explored in the SSRN preprint One New Long COVID Case Every Minute in the United States.
Why Lyme Disease Prevalence Is Underestimated
Traditional Lyme disease estimates rely on reported infections and early-stage diagnosis captured through passive surveillance systems. While useful for tracking trends, these models fail to reflect how Lyme disease presents in real-world clinical settings. Early-stage infection is frequently missed due to non-specific symptoms, limited test sensitivity, and variability in clinical suspicion across providers (Hinckley et al., 2014; Steere et al., 2016).
At the same time, Lyme disease does not follow a single, uniform clinical pattern. Patients often present across neurological, autonomic, inflammatory, musculoskeletal, and cognitive domains, with symptoms shifting over time. This heterogeneity increases the likelihood of under-recognition and fragmented care, particularly when patients are evaluated within narrow specialty frameworks. This variability is explored further in our Lyme Disease Phenotypes paper, which maps the multidimensional nature of disease presentation.
A substantial subset of patients develops persistent or relapsing illness, often described as post-treatment Lyme disease syndrome (PTLDS) or chronic Lyme. These patients are not consistently tracked in surveillance systems and are frequently misclassified under autoimmune, neurological, or psychiatric diagnoses (Rebman and Aucott, 2020; Aucott et al., 2013). The result is a layered undercount. Early cases are missed, late-stage cases are misclassified, and complex presentations fall out of structured surveillance entirely. Observed prevalence reflects visible burden, while total burden remains obscured.
The US-CCUC™ Lyme Prevalence Formula
The US-CCUC™ model reframes disease prevalence by accounting for underdiagnosis, diagnostic fragmentation, and chronic disease trajectories. Rather than treating Lyme disease as a series of isolated annual infections, this framework models total active disease burden, including persistent and relapsing illness. Under this approach, prevalence is understood as a cumulative outcome shaped by detection systems, disease persistence, and misclassification across clinical domains.
Formula:
Corrected Lyme burden = annual Lyme diagnoses × active persistence window × retention factor
Simplified:
Corrected prevalence = accumulated active burden across diagnosed, missed, and persistent cases
The purpose of this formula is not to treat Lyme disease as a static yearly infection count, but to model the accumulated burden of active illness over time. In practice, prevalence is shaped not only by how many new cases occur in a given year, but by how long patients remain symptomatic, how often cases are missed or delayed, and how frequently persistent disease is fragmented across other diagnostic categories. Under US-CCUC™, corrected prevalence therefore reflects a bounded chronic illness population rather than a simple sum of reported annual infections. This produces a more realistic estimate of how many Americans are actually living with Lyme-related illness, not just how many cases are captured in annual surveillance.
Core Inputs for Lyme Disease Prevalence
Current U.S. estimates suggest approximately 400,000 to 500,000 Lyme diagnoses annually (CDC, 2024; Kugeler et al., 2021). However, this reflects only diagnosed cases rather than total infections. A correction must account for missed early infections, diagnostic delays, and variability in access to care. More importantly, Lyme disease burden is heavily shaped by a large population of patients living with persistent or relapsing illness. CYNAERA’s broader IACC prevalence modeling places the chronic Lyme and PTLDS population at approximately 5 to 7 million Americans, reflecting long-term disease burden that is not captured in traditional surveillance frameworks
Worked Math Box — Lyme Disease (US-CCUC™)
Formula:
Corrected Lyme burden = annual Lyme diagnoses × active persistence window × retention factor
Inputs:
Annual Lyme diagnoses = 450,000Active persistence window = 10 to 12 years
Retention factor = 0.9 to 1.3
Step-by-step calculation:
Low-end estimate:450,000 × 10 = 4,500,0004,500,000 × 0.9 = 4,050,000
High-end estimate:450,000 × 12 = 5,400,0005,400,000 × 1.3 = 7,020,000
Rounded corrected U.S. Lyme burden: Approximately 5 to 7 million Americans
Interpretation:
This model treats Lyme burden as an accumulated active disease population rather than a single-year infection count. The persistence window reflects the number of years cases continue to contribute to active burden, while the retention factor accounts for variation in recovery, relapse, underdiagnosis, and long-term persistence. Under US-CCUC™, Lyme is modeled as a bounded chronic illness population, which is why the corrected national estimate lands at approximately 5 to 7 million Americans.
Diagnostic Gaps and the Diagnostic Multiplier™
While US-CCUC™ corrects for population-level undercount, the Diagnostic Multiplier™ (DM™) helps explain why Lyme disease is so inconsistently captured in clinical systems. Diagnosis is shaped by real world factors including access to care, physician education, testing limitations, and clinical interpretation (National Academies of Sciences, Engineering, and Medicine, 2017). Lyme disease is particularly affected by early stage test limitations, regional variability in clinical familiarity, dependence on specialist referral, and symptom overlap with other chronic conditions.
This diagnostic fragmentation means that disease burden is often distributed across multiple clinical categories rather than recognized as a unified condition. CYNAERA’s Composite Diagnostic Fingerprint for Lyme disease addresses this issue by capturing multisystem burden across domains, providing a more integrated approach to identifying patients who might otherwise be missed or misclassified. Together, these factors reduce diagnostic capture and create a measurable gap between observed and actual disease burden. The Diagnostic Multiplier™ framework formalizes this gap and reinforces that Lyme prevalence is influenced by system performance as much as biology .
Lyme Disease and the Post-Infectious Illness Model
The COVID-19 pandemic has validated post-infectious chronic illness at scale. Long COVID has demonstrated that infection can trigger persistent multisystem disease, often following relapsing-remitting trajectories and remaining underrecognized within traditional healthcare models (Davis et al., 2023; Komaroff and Bateman, 2021). These patterns closely align with long-standing observations in Lyme disease. Rather than representing a new phenomenon, Long COVID has clarified that Lyme, ME/CFS, and related conditions exist within a broader category of infection-associated chronic conditions. CYNAERA’s IACC prevalence work further supports this unified framework, demonstrating consistent patterns of underdiagnosis and chronic disease burden across conditions.
Why Correct Lyme Prevalence Matters
Correcting Lyme disease prevalence has implications beyond surveillance. Research funding decisions are tied to perceived disease burden, meaning underestimation can lead to chronic underinvestment. Clinical trial design depends on accurate population modeling, particularly for heterogeneous and relapsing conditions. Understanding the true scale of Lyme disease also informs how interventions are developed. As disease burden becomes more clearly defined, it enables more precise modeling of subgroup-specific treatment approaches, including remission-oriented strategies such as personalized CRISPR Remission for Lyme Disease.
At the policy level, prevalence estimates shape disability determination, insurance coverage, and healthcare resource allocation. Recognizing the true scale of Lyme disease reframes it from a regional infectious concern to a national chronic illness burden.
Conclusion
The data necessary to understand Lyme disease prevalence already exists across epidemiology, clinical research, and patient-reported experience. What has been missing is a framework to integrate these findings into a coherent model. The US-CCUC™ framework provides that integration by correcting for underdiagnosis, misclassification, and chronic disease trajectories. When applied to Lyme disease, it reveals a substantially larger burden than official estimates suggest.
Lyme disease is not rare, narrowly defined, or fully captured by existing systems. It is a complex, underrecognized chronic condition affecting 5 to 7 million American adults. The question is no longer whether Lyme disease is undercounted, but whether our healthcare systems are prepared to recognize and respond to its true scale.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Centers for Disease Control and Prevention (CDC) (2024) Lyme Disease Data and Surveillance.
Kugeler, K.J. et al. (2021) ‘Estimating the frequency of Lyme disease diagnoses in the United States’, Emerging Infectious Diseases, 27(2), pp. 616–619
Nelson, C.A. et al. (2015) ‘Incidence of clinician-diagnosed Lyme disease, United States’, Emerging Infectious Diseases, 21(9), pp. 1625–1631
Hinckley, A.F. et al. (2014) ‘Lyme disease testing by large commercial laboratories in the United States’, Clinical Infectious Diseases, 59(5), pp. 676–681
Adrion, E.R. et al. (2015) ‘Health care costs, utilization and patterns of care following Lyme disease’, PLoS ONE, 10(2)
Aucott, J.N. et al. (2013) ‘Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning’, Frontiers in Medicine
Rebman, A.W. and Aucott, J.N. (2020) ‘Post-treatment Lyme disease as a model for persistent symptoms’, Frontiers in Medicine
Marques, A. (2008) ‘Chronic Lyme disease: a review’, Infectious Disease Clinics of North America, 22(2), pp. 341–360
Steere, A.C. et al. (2016) ‘Lyme borreliosis’, Nature Reviews Disease Primers, 2
Feder, H.M. et al. (2007) ‘A critical appraisal of “chronic Lyme disease”’, New England Journal of Medicine, 357(14), pp. 1422–1430
Proal, A.D. and VanElzakker, M.B. (2021) ‘Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors’, Frontiers in Microbiology, 12
Choutka, J. et al. (2022) ‘Unexplained post-acute infection syndromes’, Nature Medicine, 28, pp. 911–923
National Academies of Sciences, Engineering, and Medicine (2017) Global Health and the Future Role of the United States
Institute of Medicine (2015) Improving Diagnosis in Health Care. Washington, DC
Newman-Toker, D.E. et al. (2021) ‘Diagnostic errors and harm across medical settings’, BMJ Quality & Safety, 30, pp. 1–11
Davis, H.E. et al. (2023) ‘Long COVID: major findings and mechanisms’, Nature Reviews Microbiology
Komaroff, A.L. and Bateman, L. (2021) ‘Will COVID-19 lead to ME/CFS?’, Frontiers in Medicine
Comments